News

TDR is said to be a world leader in medicinal and combinatorial chemistry and provides products and services that are complementary to CBI's existing offerings in biologics and custom peptides.

The use of the flexible and modular Microlab® Star enables AstraZeneca to use one instrument for diverse applications ranging from compound dilution to assay construction.

The studies will enable Can-Fite to treat rheumatoid arthritis patients in future Phase III clinical trials for prolonged periods of time as required in various Phase III studies.

Xceleron has signed an agreement with Sanofi-Aventis to assess the human metabolism of compounds in early clinical development.

QIAGEN and Digene have announced a definitive agreement to combine the two companies to create market- and technology-leadership in molecular diagnostics.

The 2007 Carl Brändén Award was presented to Prof. Lubert Stryer for his exceptional contributions to education in biochemistry and molecular biology.

New findings explain how lipid-like peptides interact with lipid molecules and may provide new strategies for the encapsulation and the delivery of biological active materials.

The long-term goal of the initiative is to shed light on the causes of complex disorders and diseases and develop new approaches for treating them.

The research agreement between Immunicon and Bristol-Myers Squibb involve protein and molecular targets associated with circulating tumor cells.

The data from a Phase I clinical study of anti-cancer drug candidate has been published in the 2007 American Society for Clinical Oncology Proceedings.